NEW YORK (GenomeWeb) – Qiagen said on Tuesday that it has received CE-IVD marking for its Therascreen PITX2 RGQ PCR kit and launched the assay in Europe.

The new kit is a methylation assay intended to help predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. It runs on Qiagen's Rotor-Gene Q MDx real-time thermal cycler and can easily be adopted by customers already running Therascreen assays on the company's QIAsymphony automation platform.